Cannabis Strategic Ventures NUGS OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score

23/100

1/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Cannabis Strategic Ventures (NUGS) .

Criteria proven by this page:

VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.

Overall SharesGrow Score: 22/100 with 1/7 criteria passed.

SharesGrow 7-Criteria Score

23/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

✗

PAST

0/100

→ Income

✗

HEALTH

0/100

Debt-to-Equity & liquidity

→ Health

✗

MOAT

15/100

→ Income

✓

GROWTH

90/100

→ Income

✗

INCOME

10/100

→ Income

Valuation Snapshot — NUGS

Valuation Multiples

P/E (TTM)0.0

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio0.00

P/S Ratio0.04

EV/EBITDA0.0

Per Share Data

EPS (TTM)$-0.03

Book Value / Share$0.00

Revenue / Share$0.03

FCF / Share$0.00

Yields & Fair Value

Earnings YieldN/A

Dividend Yield0.00%

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2005	$-3.00	$11.18K	$-6.68M	-59771%
2013	$0.00	$372.11K	$49.21K	13.2%
2014	$0.00	$149.56K	$11.81K	7.9%
2015	$0.00	$0.00	$-73.78K	-
2016	$0.00	$0.00	$85.97K	-
2017	$0.00	$344.7K	$-8.41M	-2439.8%
2018	$-0.08	$701.97K	$-21.43M	-3053.3%
2019	$-0.04	$2.37M	$-9.06M	-382.6%
2020	$-0.02	$14.6M	$-5.64M	-38.6%
2021	$-0.03	$9.85M	$-8.6M	-87.3%